IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase

doi:10.4254/wjh.v5.i11.635

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 5, Issue 11

This Article

Academic Content and Language Evaluation of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (4808)

All Articles published online

The chart showing PDF series, HTML series, Figures (1-1) series, Tables (1-4) series.

Item

Count

PDF

250

HTML

2453

Figures (1-1)

231

Tables (1-4)

239

Sum=3173

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

863

Download

772

Sum=1635

Nov 27, 2013 (publication date) through Dec 26, 2024

Times Cited of This Article

Times Cited (1)

Journal Information of This Article

Publication Name

World Journal of Hepatology

ISSN

1948-5182

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Brief Article

World J Hepatol. Nov 27, 2013; 5(11): 635-641
Published online Nov 27, 2013. doi: 10.4254/wjh.v5.i11.635

Table 1 Patient baseline and demographic characteristics, and treatment response in the present study

	Total	PNALT	Abnormal ALT	P value
Number of patients	278	100	178
Age (yr)	55.6 ± 11.4	56.2 ± 10.9	55.3 ± 11.6	0.526
Gender (male/female)	136/142	31/69	105/73	< 0.0001
AST (IU/L)	56.6 ± 44.7	29.8 ± 12.1	71.3 ± 49.1	< 0.0001
ALT (IU/L)	70.5 ± 64.3	27.6 ± 7.2	94.6 ± 69.4	< 0.0001
γ-GT (IU/L)	50.7 ± 57.3	26.2 ± 22.1	64.1 ± 65.7	< 0.0001
WBC (/mm³)	5190 ± 1500	5060 ± 1490	5260 ± 1510	0.28
Hemoglobin (g/dL)	14.4 ± 7.1	13.5 ± 1.2	15.0 ± 8.9	0.094
Platelets (× 10⁴/mm³)	17.1 ± 5.6	17.7 ± 5.9	16.8 ± 5.5	0.20
Previous treatment (-/+)	211/67	75/25	136/42	0.90
IL-28B SNP(Maj/Min)	189/89	70/30	119/59	0.68
VR/Null response	203/65	84/16	129/49	0.042
RVR (+/-)	32/200	12/70	20/130	0.93
EVR (+/-)	116/118	46/36	70/82	0.18
SVR (+/-)	143/135	56/44	87/91	0.30

Data are expressed as the mean ± SD. P values are for comparisons between the persistent normal alanine aminotransferase (PNALT)- and abnormal alanine aminotransferase (ALT)-groups by Student’s t-test or χ² test. AST: Aspartate aminotransferase; γ-GT: Gamma-glutamyl transpeptidase; WBC: White blood cell count; IL-28B: Interleukin 28B; SNP: single-nucleotide polymorphisms; Maj: Major genotype; Min: Minor genotype; VR: Virologic response; RVR: Rapid virologic response; EVR: Early virologic response; SVR: Sustained virologic response.

Table 2 Baseline characteristics of hepatitis C virus-infected patients, according to interleukin 28B single-nucleotide polymorphism rs8099917

IL-28B rs8099917	PNALT group (n = 100)			Abnormal ALT group (n = 178)
	Major	Minor	P value	Major	Minor	P value
Number of patients	70	30		119	59
Age (yr)	57.7 ± 10.8	52.6 ± 10.5	0.031	55.3 ± 11.3	55.4 ± 12.3	0.95
Gender (male/female)	21/49	10/20	0.92	68/51	37/22	0.58
AST (IU/L)	29.3 ± 13.1	30.9 ± 9.7	0.58	69.4 ± 51.4	75.4 ± 44.1	0.47
ALT (IU/L)	26.8 ± 7.2	29.5 ± 7.0	0.086	92.1 ± 70.4	99.5 ± 67.8	0.5
γ-GT (IU/L)	21.0 ± 11.5	38.4 ± 33.8	0.00069	54.0 ± 41.3	85.1 ± 95.7	0.0056
WBC (/mm³)	5130 ± 1440	4900 ± 1640	0.52	5280 ± 1,680	5230 ± 1070	0.84
Hemoglobin (g/dL)	13.3 ± 1.0	13.9 ± 1.5	0.02	15.3 ± 10.8	14.4 ± 1.1	0.52
Platelets (× 10⁴/mm³)	17.2 ± 5.7	18.8 ± 6.3	0.21	17.0 ± 5.3	16.4 ± 5.8	0.49
Previous treatment (-/+)	54/16	21/9	0.61	93/26	43/16	0.55
VR/Null response	63/7	21/9	0.027	98/21	31/23	0.000059
RVR (+/-)	9/50	3/20	0.92	17/84	3/46	0.12
EVR (+/-)	38/21	8/15	0.029	59/44	11/38	0.00011
SVR (+/-)	44/26	12/18	0.058	67/52	20/39	0.0079

Data are expressed as the mean ± SD. P values are for comparisons between the major genotype group and minor genotype group among the persistent normal alanine aminotransferase (PNALT) group or among abnormal alanine aminotransferase (ALT) group by Student’s t-test or the χ² test. AST: Aspartate aminotransferase; γ-GT: Gamma-glutamyl transpeptidase; WBC: White blood cell count; IL-28B: Interleukin 28B; Maj: Major genotype; Min: Minor genotype; VR: Virologic response; RVR: Rapid virologic response; EVR: Early virologic response; SVR: Sustained virologic response.

Table 3 Hepatitis C virus genotype 1-infected patient with persistent normal alanine aminotransferase and interleukin 28B single-nucleotide polymorphism

IL-28B rs8099917	Major	Minor	P value	SVR	Non-SVR	P value
Number of patients	54	18		36	36
Age (yr)	58.4 ± 10.9	54.6 ± 11.0	0.20	56.6 ± 13.4	58.4 ± 8.0	0.49
Gender (male/female)	17/37	7/11	0.77	14/22	10/26	0.45
AST (IU/L)	30.3 ± 14.5	34.5 ± 10.3	0.29	13.2 ± 1.1	32.0 ± 6.3	< 0.00010
ALT (IU/L)	27.5 ± 6.7	31.7 ± 5.6	0.019	27.3 ± 7.4	29.8 ± 5.7	0.11
γ-GT (IU/L)	21.7 ± 11.9	47.3 ± 39.3	0.00024	19.7 ± 10.6	39.2 ± 32.7	0.0011
WBC (/mm³)	5020 ± 1410	4570 ± 1350	0.27	5000 ± 1350	4780 ± 1470	0.51
Hemoglobin (g/dL)	13.3 ± 0.9	13.7 ± 1.5	0.17	13.2 ± 1.1	13.5 ± 1.1	0.25
Platelets (× 10⁴/mm³)	16.6 ± 6.0	17.0 ± 5.6	0.80	17.1 ± 6.0	16.2 ± 5.8	0.51
Previous Treatment (-/+)	42/12	12/6	0.52	29/7	25/11	0.41
VR/Null response	46/8	9/9	0.0064	36/0	19/17	< 0.00010
RVR (+/-)	6/38	0/16	0.28	6/27	0/27	0.057
EVR (+/-)	25/19	1/15	0.0013	23/10	3/24	< 0.00010
SVR (+/-)	34/20	2/16	0.00040
IL-28B SNP rs8099917
(Maj/Min)				34/2	20/16	0.00040

Data are expressed as the mean ± SD. P values are for comparisons between the major genotype group and minor genotype group or between sustained virologic response (SVR) and non-SVR groups by Student’s t-test or the χ² test. AST: Aspartate aminotransferase; γ-GT: Gamma-glutamyl transpeptidase; WBC: White blood cell count; IL-28B: Interleukin 28B; Maj: Major genotype; Min: Minor genotype; VR: Virologic response; RVR: Rapid virologic response; EVR: Early virologic response; SVR: Sustained virologic response.

Table 4 Factors associated with sustained virologic response among hepatitis C virus genotype 1-infected patients with persistent normal alanine aminotransferase by multivariate analysis

Factor	Category	Odds ratio	95%CI	P value
IL-28B rs8099917	Major/Minor	7.11	1.305-38.799	0.023
EVR	(+/-)	13.28	3.242-54.399	0.0003

IL-28B: Interleukin 28B; Maj: Major genotype; Min: Minor genotype; EVR: Early virologic response.

Citation: Miyamura T, Kanda T, Nakamura M, Jiang X, Wu S, Nakamoto S, Mikami S, Takada N, Imazeki F, Yokosuka O. IL-28B polymorphisms and treatment response in hepatitis C virus patients with persistently normal alanine aminotransferase. World J Hepatol 2013; 5(11): 635-641
URL: https://www.wjgnet.com/1948-5182/full/v5/i11/635.htm
DOI: https://dx.doi.org/10.4254/wjh.v5.i11.635